Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

scientific article

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1176/APPI.AJP.2009.09070932
P698PubMed publication ID20360315
P5875ResearchGate publication ID42833540

P50authorMark LathropQ6768494
Peter McGuffinQ7175787
Pierandrea MugliaQ89919709
Piotr M CzerskiQ90589643
Daniel SoueryQ92151258
Nader PerroudQ103779206
Borut JermanQ114301483
Anna PlacentinoQ114432657
Astrid ZobelQ114561208
Katrina PirloQ125264192
Cathryn LewisQ16731445
Marcella RietschelQ20742720
Ian W. CraigQ30506522
Michael R. BarnesQ37650961
Katherine J. AitchisonQ37828818
Ole MorsQ41638422
Rudolf UherQ43273047
Sarah Cohen-WoodsQ44547557
Neven HenigsbergQ45729464
Gerome BreenQ47502400
Erik Roj LarsenQ56380953
Amy ButlerQ58098008
Thomas G. SchulzeQ61995101
Joanna Twarowska-HauserQ89213422
P2093author name stringAnne Farmer
Wolfgang Maier
Tina Zagar
Mandy Y M Ng
P2860cites workConduct disorder and ADHD: evaluation of conduct problems as a categorical and quantitative trait in the international multicentre ADHD genetics studyQ28943364
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)555-564
P577publication date2010-04-01
P1433published inAmerican Journal of PsychiatryQ1935368
P1476titleGenome-wide pharmacogenetics of antidepressant response in the GENDEP project
P478volume167

Reverse relations

cites work (P2860)
Q36541051A dialogue between the immune system and brain, spoken in the language of serotonin
Q92384370A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression
Q64281271A genome-wide association meta-analysis of prognostic outcomes following cognitive behavioural therapy in individuals with anxiety and depressive disorders
Q34347951A genome-wide association study of a sustained pattern of antidepressant response
Q28597255A genome-wide association study of antidepressant response in Koreans
Q89747545A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping
Q39021015ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis
Q48468840ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway.
Q37388467Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-β mRNA Levels Accurately Predict Treatment Response in Depressed Patients.
Q48377309An association and haplotype analysis of porcine maternal infanticide: a model for human puerperal psychosis?
Q31130220Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response
Q48617573Analysis of 34 candidate genes in bupropion and placebo remission.
Q91635696Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder
Q54966148Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables.
Q33930731Antidepressant treatment response is modulated by genetic and environmental factors and their interactions
Q37986775Assessing gene-gene interactions in pharmacogenomics
Q38540142BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients.
Q38171656Behavior genetics: past, present, future
Q47659995Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.
Q38269353Biomarker studies and the future of personalized treatment for depression
Q47671635Biomarkers for Major Depressive Disorder: Economic Considerations
Q36593269Biomarkers predicting treatment outcome in depression: what is clinically significant?
Q34247513Biomarkers to predict antidepressant response
Q47555879Blood-based biomarkers predicting response to antidepressants.
Q47652242Blue Genes? Understanding and Mitigating Negative Consequences of Personalized Information about Genetic Risk for Depression
Q36539999Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'.
Q24202141Citalopram versus other anti-depressive agents for depression
Q27001088Cognitive mechanisms of treatment in depression
Q47239298Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity
Q38823641Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response
Q34292369Convergent evidence from mouse and human studies suggests the involvement of zinc finger protein 326 gene in antidepressant treatment response
Q48367416Copy number variants and therapeutic response to antidepressant medication in major depressive disorder.
Q34975631Copy number variants in pharmacogenetic genes
Q34708116Cytokine variations and mood disorders: influence of social stressors and social support
Q37201357DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP
Q38070163Do we need pharmacogenetics to personalize antidepressant therapy?
Q102369303ERICH3: vesicular association and antidepressant treatment response
Q38211978Early switching strategies in antidepressant non-responders: current evidence and future research directions.
Q46011308Effects of antidepressant drug exposure on gene expression in the developing cerebral cortex.
Q51690060Epidemiology, epigenetics and the 'Gloomy Prospect': embracing randomness in population health research and practice.
Q34426216Epigenetic alterations in depression and antidepressant treatment
Q38504484Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge
Q38504481Escitalopram modulates neuron-remodelling proteins in a rat gene-environment interaction model of depression as revealed by proteomics. Part I: genetic background
Q38394152Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design
Q24632901Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains
Q26991710Exploring the effects of polymorphisms on cis-regulatory signal transduction response
Q27015830From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment
Q38154917Gene expression: biomarker of antidepressant therapy?
Q38067101Gene × environment interactions in the prediction of response to antidepressant treatment
Q37971344Gene-environment interaction in major depression and antidepressant treatment response
Q58786918Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP)
Q37483043Genetic Contributions of Inflammation to Depression
Q45729383Genetic differences in cytochrome P450 enzymes and antidepressant treatment response
Q48372657Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.
Q28484419Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis
Q35023117Genetic relationships between suicide attempts, suicidal ideation and major psychiatric disorders: a genome-wide association and polygenic scoring study
Q44478530Genetic susceptibility for bipolar disorder and response to antidepressants in major depressive disorder
Q35653883Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs
Q48070708Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder
Q47213690Genetics and psychiatry: a proposal for the application of the precautionary principle
Q38410122Genetics in child and adolescent psychiatry: methodological advances and conceptual issues
Q37603806Genome-wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium
Q36973699Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response
Q38444447Genome-wide association studies in pharmacogenomics of antidepressants
Q101237251Genome-wide association studies of antidepressant class response and treatment-resistant depression
Q35074796Genome-wide association studies of antidepressant outcome: a brief review
Q35993192Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway
Q64444709Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP
Q21134099Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13)
Q49024786Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project.
Q37223300Genome-wide association study of response to cognitive-behavioural therapy in children with anxiety disorders.
Q39589817Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker
Q39293823Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers
Q37045112Genome-wide scan of job-related exhaustion with three replication studies implicate a susceptibility variant at the UST gene locus
Q45729483Genomewide interaction and enrichment analysis on antidepressant response
Q34555598Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics
Q35592683High dimensional endophenotype ranking in the search for major depression risk genes
Q33697992Highly polygenic architecture of antidepressant treatment response: Comparative analysis of SSRI and NRI treatment in an animal model of depression
Q40504312IL6-174G > C genetic polymorphism influences antidepressant treatment outcome
Q37200660Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models
Q37223293Immune signatures and disorder-specific patterns in a cross-disorder gene expression analysis
Q38044323Implications of the use of genetic tests in psychiatry, with a focus on major depressive disorder: a review
Q50786215Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response.
Q37961088Integrative genomics strategies to elucidate the complexity of drug response
Q35150183Investigation of blood mRNA biomarkers for suicidality in an independent sample
Q34731202Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates
Q37182897Machine learning, statistical learning and the future of biological research in psychiatry
Q36096664Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Q47118154MicroRNA-Mediated Regulation of ITGB3 and CHL1 Is Implicated in SSRI Action
Q38694557Neurobehavioral comorbidities of epilepsy: Role of inflammation.
Q47436767New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.
Q48102611No support for replication of the genetic variants identified by a recent mega-analysis of the treatment response to antidepressants.
Q38317241Novel investigational drugs targeting IL-6 signaling for the treatment of depression
Q43568484Overlapping effects of genetic variation and epigenetics on drug response: challenges of pharmacoepigenomics
Q38657429Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks
Q92710468Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis
Q37789098Personalized medicine for depression: can we match patients with treatments?
Q38756015Personalized medicine: Genetic risk prediction of drug response
Q35952370PharmGKB summary: citalopram pharmacokinetics pathway
Q42926677Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population
Q92907278Pharmacogenetics and Depression: A Critical Perspective
Q37956206Pharmacogenetics in psychiatry: translating research into clinical practice.
Q38121519Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research
Q37989490Pharmacogenetics of antidepressant drugs: current clinical practice and future directions
Q34155796Pharmacogenetics of antidepressant response
Q35026088Pharmacogenetics of antidepressants
Q38484370Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications
Q38139479Pharmacogenetics of mood disorders: what clinicians need to know
Q37658586Pharmacogenomics and patient care: one size does not fit all.
Q27001573Pharmacogenomics discovery and implementation in genome-wide association studies era
Q42361493Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry
Q37614819Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics
Q89329295Pharmacogenomics: A focus on antidepressants and atypical antipsychotics
Q38099042Pharmacological management of unipolar depression
Q35032056Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.
Q47624828Pharmacoproteomic investigation into antidepressant response in two mouse inbred strains
Q36583679Polygenic interactions with environmental adversity in the aetiology of major depressive disorder.
Q57303389Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts
Q38258243Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs.
Q48682021Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder.
Q38814860Precision medicine for psychopharmacology: a general introduction
Q28710054Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial
Q30249569Progress and prospects in pharmacogenetics of antidepressant drugs
Q47666907Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years
Q45390458Proinflammatory and "resiliency" proteins in the CSF of patients with major depression.
Q26825110Proteoglycans and neuronal migration in the cerebral cortex during development and disease
Q35117863Putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients
Q34131354Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice
Q34459775Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels
Q34343309Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis
Q38845473Separate and combined effects of genetic variants and pre-treatment whole blood gene expression on response to exposure-based cognitive behavioural therapy for anxiety disorders
Q34473840Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders
Q35755912Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR.
Q45022135Summaries of plenary, symposia, and oral sessions at the XXII World Congress of Psychiatric Genetics, Copenhagen, Denmark, 12-16 October 2014.
Q64249357Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk
Q47912001Systems genetics analysis of pharmacogenomics variation during antidepressant treatment.
Q37213132TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
Q89747287Targeted exome sequencing identifies five novel loci at genome-wide significance for modulating antidepressant response in patients with major depressive disorder
Q38189135Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?
Q37072176Testing a machine-learning algorithm to predict the persistence and severity of major depressive disorder from baseline self-reports.
Q35715254The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.
Q55113792The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response Study: Design and Methodology.
Q89510117The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review
Q38453405The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study
Q37914871The genetic blueprint of major depressive disorder: contributions of imaging genetics studies
Q38187699The inflammatory cytokines: molecular biomarkers for major depressive disorder?
Q58864945The norepinephrine transporter gene is a candidate gene for panic disorder
Q36618462Therapygenetics: Using genetic markers to predict response to psychological treatment for mood and anxiety disorders
Q38956222Toward a Global Roadmap for Precision Medicine in Psychiatry: Challenges and Opportunities.
Q92431605Treatment response classes in major depressive disorder identified by model-based clustering and validated by clinical prediction models
Q34424865Understanding the pharmacogenetics of selective serotonin reuptake inhibitors
Q47668646Unpacking Major Depressive Disorder: From Classification to Treatment Selection
Q37446677Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder
Q37016538Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients
Q38154916Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment.
Q37880738What little we know about tailoring depression treatment for individual patients
Q47830777Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression.
Q49567721[Pharmacogenetics in psychiatry: state of the art].

Search more.